Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Energy and Renewables
  • IT & Communications
  • Chemicals & Materials
  • Pharma & Biotech
  • Medical Equipment & Supplies

University

  • King's College London
  • Queen Mary, University of London
  • University of Bath
  • University of Bristol
  • University of Cardiff (Fusion IP)
  • University of Glasgow
  • University of Leeds
  • University of Oxford
  • University of Sheffield (Fusion IP)
  • University of Southampton
  • University of Surrey
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • Top 10 Holdings
    by value

Search keyword

Medical Equipment & Supplies

University: Bristol

Company Stage: Private (post-seed)

Website: http://www.azellon-ltd.com

Azellon Cell Therapeutics

Azellon is a spin-out company from The University of Bristol focused on the research, development and commercialisation of an adult autologous (patient's own) stem cell technology which in vitro (tissue culture) has shown great promise for the healing of meniscal tears.

As at 30 June 2011

IP Group holding

  

25.4%

Holding represents undiluted beneficial equity interest excluding debt

Related news

14 Nov 2011
Azellon Cell Therapeutics Ltd – To commence human Phase I/IIa clinical trial of stem cell therapy

There is currently no news available.

More portfolio news